Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of selumetinib hydrosulfate after surgery in adults with neurofibromatosis type 1
ChiCTR2400093647Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: 2-year progression-free survival rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on ChiCTR2400093647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093647.